Allogene Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
Allogene Therapeutics, Inc. carries a market capitalization of 449.14M, placing it among publicly traded companies globally. Its enterprise value stands at 456.07M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 449.14M |
| Enterprise Value | 456.07M |
Share Statistics
Allogene Therapeutics, Inc. currently has 345.35M shares outstanding.
| Shares Outstanding | 345.35M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 114.01, and the price-to-book ratio stands at 1.65.
| PE Ratio | N/A |
| PS Ratio | 114.01 |
| PB Ratio | 1.65 |
| P/TBV Ratio | 1.65 |
| P/FCF Ratio | -5.20 |
| P/OCF Ratio | -5.18 |
Enterprise Valuation
| EV / Sales | 98.29 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Allogene Therapeutics, Inc. maintains a current ratio of 10.72, meaning it holds 10.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 16.13, indicating elevated leverage, while an interest coverage ratio of -129.73 demonstrates limited ability to service its debt obligations.
| Current Ratio | 10.72 |
| Quick Ratio | 10.48 |
| Debt / Equity | 16.13 |
| Debt / EBITDA | -0.42 |
| Interest Coverage | -129.73 |
Financial Efficiency
| Return on Equity (ROE) | -42.39 |
| Return on Assets (ROA) | -32.43 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Allogene Therapeutics, Inc.'s stock has gained approximately 0.7751938% over the past 52 weeks. The 50-day moving average sits at 1.77, while the 200-day moving average is 1.99.
| Beta (5Y) | N/A |
| 52-Week Price Change | 0.7751938% |
| 50-Day Moving Average | 1.77 |
| 200-Day Moving Average | 1.99 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Allogene Therapeutics, Inc. generated 4.64M in revenue and converted that into -165.49M in net income, yielding earnings per share of -0.65. EBITDA reached -168.65M, while operating income came in at -180.32M.
| Revenue | 4.64M |
| Gross Profit | N/A |
| Operating Income | -180.32M |
| Pretax Income | -165.49M |
| Net Income | -165.49M |
| EBITDA | -168.65M |
| EBIT | -180.32M |
| Earnings Per Share (EPS) | -0.65 |
Balance Sheet
Allogene Therapeutics, Inc. holds 332.60M in cash and equivalents against 70.35M in total debt, resulting in a net debt position of -38.63M. Total book value stands at 436.18M, with working capital of 308.27M providing operational flexibility.
| Cash & Cash Equivalents | 332.60M |
| Total Debt | 70.35M |
| Net Debt | -38.63M |
| Equity (Book Value) | 436.18M |
| Book Value Per Share | 1.26 |
| Working Capital | 308.27M |
Cash Flow
Allogene Therapeutics, Inc. produced -102.20M in operating cash flow over the past twelve months. After subtracting -402,000.00 in capital expenditures, free cash flow totaled -102.60M - equivalent to -0.40 per share.
| Operating Cash Flow | -102.20M |
| Capital Expenditures | -402,000.00 |
| Free Cash Flow | -102.60M |
| FCF Per Share | -0.40 |
Margins
Allogene Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -3,886.14 and net profit margin of -3,566.68 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -3,886.14 |
| Pretax Margin | -3,566.68 |
| Profit Margin | -3,566.68 |
| EBITDA Margin | -3,634.68 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -30.64 |
| FCF Yield | -19.24 |
Scores
Allogene Therapeutics, Inc. posts an Altman Z-Score of -1.95, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -1.95 |